> Á¤º¸¼¾ÅÍ > ¼¼¹Ì³ª/Çà»ç
Á¦¸ñ | 2022³â 5¿ù 12ÀÏ »ý¹°Á¤º¸ÇÐ ¼¼¹Ì³ª | ||
---|---|---|---|
ÀÛ¼ºÀÚ | °ü¸®ÀÚ | ÀÛ¼ºÀÏ | 2022-05-10 |
¼¿ï´ëÇб³ »ý¹°Á¤º¸ÇÐ Çùµ¿°úÁ¤ ÁÖÃÖ·Î ¼¼¹Ì³ª¸¦ ¾Æ·¡¿Í °°ÀÌ ¿°íÀÚ ÇÏ¿À´Ï ¸¹Àº Âü¿© ¹Ù¶ø´Ï´Ù. ¼¼¹Ì³ª´Â ZoomÀ» ÅëÇÑ ¿Â¶óÀÎ °ÀÇ·Î ¿¹Á¤µÇ¾î ÀÖÀ¸¸ç °ÀÇ¿¡ Âü¿©ÇÏ°íÀÚ ÇϽô ºÐ²²¼´Â ¾Æ·¡ÀÇ ¸µÅ©·Î Âü¿© ºÎŹµå¸®°Ú½À´Ï´Ù. ÀϽÃ: 2022³â 5¿ù 12ÀÏ ¸ñ¿äÀÏ ¿ÀÀü 11½Ã ¿¬»ç: ¹æµÎÈñ ¿¬»ç´Ô (¿¬¼¼´ëÇб³) Zoom link:¡¡https://snu-ac-kr.zoom.us/j/96027213207 Title:¡¡Cell-free tumor dna as a cancer surveillance strategy Recent studies on ctDNA have shown that the "liquid biopsy" is very attractive for monitoring of minimal residual cancers that cannot be sampled without invasive means. However, mutations from the tumor comprise only a small fraction of plasma DNA, and thus require very high-depth sequencing for reliable identification of minimal residual disease. In the presentation, we will discuss what are the optimal methods for the detection of MRD. Recently, we have actively explored mutation-based tissue informed methods; with colon cancer patient cohorts, we were able to predict relapse with high PPV. Furthermore, ctDNA based MRD analysis can be done without tissue and/or methylation-based means. We will also discuss pros/cons of strategies implementing individualized panels, pre-designed targeted panels, or genome-wide analysis.
|
|||